Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.70 |
| ▸ | RAB9A | P51151 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.70 |
| ▸ | RELA | Q04206 | 2/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | BRD4 | O60885 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | MB | P02144 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11048872 | 0.85 | DEGS1 (0.61) | NPC1RAB9ASMN1; SMN2GAATSHR | |
| SCHEMBL3713301 | 0.84 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2GAATSHR | |
| SCHEMBL2998577 | 0.82 | SMN1; SMN2 (1.00) | NPC1RAB9ASMN1; SMN2GAATSHR | |
| SCHEMBL5645657 | 0.82 | SMN1; SMN2 (0.68) | NPC1RAB9ASMN1; SMN2GAATSHR | |
| SCHEMBL17675351 | 0.82 | SMN1; SMN2 (0.68) | NPC1RAB9ASMN1; SMN2GAATSHR | |
| SCHEMBL11759969 | 0.82 | SMN1; SMN2 (0.68) | NPC1RAB9ASMN1; SMN2GAATSHR | |
| SCHEMBL4135335 | 0.82 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2GAATSHR | |
| SCHEMBL396577 | 0.82 | SMN1; SMN2 (0.67) | NPC1RAB9ASMN1; SMN2GAATSHR | |
| SCHEMBL7679084 | 0.82 | SMN1; SMN2 (0.67) | NPC1RAB9ASMN1; SMN2GAATSHR | |
| SCHEMBL2205368 | 0.79 | TGM2 (0.67) | NPC1RAB9ASMN1; SMN2GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-10-03 | — | — | US | disclosed |
| CN-112442013-B | Compound serving as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业有限公司 | 2022-07-26 | — | — | CN | disclosed |
| US-20220079926-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | CENTAURUS THERAPEUTICS | 2022-03-17 | — | — | US | disclosed |
| US-11135207-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2021-10-05 | — | — | US | disclosed |
| US-11135207-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2021-10-05 | — | — | US | disclosed |
| WO-2021043185-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-03-11 | — | — | WO | disclosed |
| US-20190328720-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | CENTAURUS THERAPEUTICS | 2019-10-31 | — | — | US | disclosed |
| US-20190328720-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | CENTAURUS THERAPEUTICS | 2019-10-31 | — | — | US | disclosed |
| WO-2018112077-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | CENTAURUS THERAPEUTICS (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079926-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | CERS2, DEGS1, SMPD1 | NPC1 59/4885RAB9A 952/4885SMN1; SMN2 588/4885 |
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, DEGS1, SMPD1 | NPC1 59/4885RAB9A 952/4885SMN1; SMN2 588/4885 |
| US-11135207-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, DEGS1, SMPD1 | NPC1 59/4885RAB9A 952/4885SMN1; SMN2 588/4885 |
| US-20190328720-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | CERS2, DEGS1, SMPD1 | NPC1 59/4885RAB9A 952/4885SMN1; SMN2 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.